RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: EVI1 overexpression is observed in ~8–10% of MDS, 8% of de novo AML, and 30% of advanced CML, but it is unclear here how EVI1 overexpression occurs61.